Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks physical decline during cancer treatment

NCT ID NCT07517211

Knowledge-focused Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study will follow 72 adults with early-stage gastroesophageal cancer to see how their physical function changes during chemotherapy. Participants will have their physical abilities measured at several points over six months. The goal is to understand which patients are at risk for losing function, so doctors can better support them during treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with early stage esophageal, gastroesophageal junction, or gastric cancer who plan to start systemic therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \* Adults ≥ 18 years old at the start of study treatment. * New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma. * Plan to start systemic therapy for resectable or potentially resectable disease. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * \* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy. * Metastatic disease at the time of diagnosis. * Patients who are unable to provide informed consent. * Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures. * Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical stage I esophageal adenocarcinoma ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal adenocarcinoma esophageal squamous cell carcinoma gastric adenocarcinoma gastric cancer gastric carcinoma gastric squamous cell carcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical stage I esophageal adenocarcinoma ajcc V8 Clinical stage I esophageal squamous cell carcinoma ajcc V8 Clinical stage I gastric cancer ajcc V8 Clinical stage I gastroesophageal junction adenocarcinoma ajcc V8 Clinical stage II esophageal adenocarcinoma ajcc V8 Clinical stage II esophageal squamous cell carcinoma ajcc V8 Clinical stage II gastric cancer ajcc V8 Clinical stage II gastroesophageal junction adenocarcinoma ajcc V8 Clinical stage III esophageal adenocarcinoma ajcc V8 Clinical stage III esophageal squamous cell carcinoma ajcc V8 Clinical stage III gastric cancer ajcc V8 Clinical stage III gastroesophageal junction adenocarcinoma ajcc V8

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.